Send me real-time posts from this site at my email

DexCom Launches CLARITY Mobile App, Strengthens CGM Profile

DexCom, Inc. DXCM recently launched its mobile application, CLARITY. Notably, Notably, this smart app is a cloud-based diabetes management software that simplifies CGM (Continuous Glucose Monitoring) data reporting and facilitates confidential sharing of data between physicians and their patients. In fact, patients can now view the same on their phones.
Clearly, this latest development is likely to fortify DexCom’s foothold in the CGM space.
About DexCom’s CGM Profile
Based in California, this medical device company is known for designing, developing and commercializing CGM systems.
Currently, DexCom’s FDA-cleared CGM system — the DexCom G4 Platinum — is driving its top line significantly. Its inbuilt features like the G4 Platinum make the DexCom G4 Platinum the most innovative CGM system in the market. Last year, DexCom announced the FDA approval of the Dexcom G5 mobile app for Android devices.
Diabetes Care Adopts Cloud-Based Services
Smart apps have made self-management and continuous monitoring of diabetes affordable through the use of cloud-based applications. These applications can show real-time data on patients’ blood glucose levels on these apps.
For instance, consumer fitness brand Fitbit FIT entered the space by a $6-million investment in Sano.
Moreover, MedTech giant Medtronic MDT collaborated with IBM to develop Sugar.IQ — a cognitive mobile personal assistant app. This application intends to provide real-time actionable glucose insights and predictions for patients with diabetes.
Also, MedTech behemoth Abbott ABT is dedicated to developing innovative products that make glucose testing easier and more accurate. Abbott’s products like Freestyle Libre, Freestyle Navigator II, Freestyle Lite, FreestyleInsulinx can be used by patients for personal glucose monitoring.
Market Prospects
In the United States, about 1.4 million new cases of diabetes are diagnosed every year.
Going by an article of Allied Market Research, the global CGM systems market is expected to see a CAGR of 22.9% between 2018 and 2024.
It also predicts that, the global market for artificial intelligence in diabetes management is expected to witness a CAGR of 50.7% between 2017 and 2023. Thus, DexCom’s latest move has been a well-timed one.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Fitbit, Inc. (FIT): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
DexCom, Inc. (DXCM): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue